WuXi XDC Cayman Inc., a leading global Contract Research, Development and Manufacturing Organisation (CRDMO) focused on the bioconjugate industry, held a grand Good Manufacturing Practice (GMP) release ceremony for its Singapore manufacturing site at Tuas Biomedical Park.
From announcing the new site in March 2024 to achieving GMP release of the BCM3 antibody intermediate and conjugated drug substance dual-function production line and the DP4 facility in August 2026, this important milestone was reached in only two and a half years.
It marks the transition of WuXi XDC’s “Global Dual-Sourcing” strategy from blueprint to reality, opening a new chapter in empowering more global clients to accelerate commercial manufacturing.
Dr Jimmy Li, CEO of WuXi XDC said, "The Singapore site will form a global collaborative network with sites in Wuxi, Shanghai, Hefei, and Suzhou, continuing to provide clients with end-to-end, one-stop CRDMO solutions for bioconjugates."
The Singapore site has a total gross floor area of approximately 25,000 square meters and serves as a core cornerstone of WuXi sXDC’s commercial production. To date, the site’s BCM3 dual-function production line and DP4 conjugated drug product facility have both successfully completed GMP release.
